产品说明书

L-Thyroxine sodium

Print
Chemical Structure| 55-03-8 同义名 : 左旋甲状腺素钠 ;T4 sodium;Levothyroxine sodium;L-T4 sodium
CAS号 : 55-03-8
货号 : A208207
分子式 : C15H10I4NNaO4
纯度 : 99%
分子量 : 798.852
MDL号 : MFCD00002596
存储条件：

粉末 Keep in dark place,Inert atmosphere,Room temperature

液体 -20°C:3-6个月-80°C:12个月
溶解度 :

DMSO: 60 mg/mL(75.11 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

H2O: 14 mg/mL(17.53 mM)，配合低频超声，并调节pH至11
动物实验配方：
生物活性
描述 L-Thyroxine sodium (Levothyroxine sodium) is a synthetic hormone for the research of hypothyroidism[3]. The topic of pharmacological interference on L-T4 (L-thyroxine) therapy addresses the patient with primary hypothyroidism, in whom periodic measurement of serum thyrotropin (TSH) is the biochemical target[4]. Compared with L-T4 alone, replacement therapy with the combination of L-T4+L-T3 (L-triiodothyronine) shows favourable changes in serum lipid profile, but higher activation of bone resorption[5]. Standard L-thyroxine supplementation in HT (Hashimoto's thyroiditis) patients exerted significant immunoregulatory effects, associated with quantitative and phenotypic changes of peripheral blood DC (dendritic cells) subpopulations[6]. The thyroid hormone affects ventricular inhomogenicity, and that L-thyroxine replacement therapy may reduce malignant ventricular arrhythmia and sudden cardiac death in primary hypothyroidism[7].
临床研究
NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT03693612 Neoplasms Phase 1 Phase 2 Recruiting June 16, 2022 United States, Massachusetts ... 展开 >> GSK Investigational Site Not yet recruiting Boston, Massachusetts, United States, 02215 Contact: US GSK Clinical Trials Call Center    877-379-3718    GSKClinicalSupportHD@gsk.com    Contact: EU GSK Clinical Trials Call Centre    877-379-3718    GSKClinicalSupportHD@gsk.com    United States, New York GSK Investigational Site Not yet recruiting New York, New York, United States, 10016- Contact: US GSK Clinical Trials Call Center    877-379-3718    GSKClinicalSupportHD@gsk.com    Contact: EU GSK Clinical Trials Call Centre    877-379-3718    GSKClinicalSupportHD@gsk.com    GSK Investigational Site Not yet recruiting New York, New York, United States, 10032 Contact: US GSK Clinical Trials Call Center    877-379-3718    GSKClinicalSupportHD@gsk.com    Contact: EU GSK Clinical Trials Call Centre    877-379-3718    GSKClinicalSupportHD@gsk.com    United States, Oklahoma GSK Investigational Site Not yet recruiting Oklahoma City, Oklahoma, United States, 73104 Contact: US GSK Clinical Trials Call Center    877-379-3718    GSKClinicalSupportHD@gsk.com    Contact: EU GSK Clinical Trials Call Centre    877-379-3718    GSKClinicalSupportHD@gsk.com    United States, Pennsylvania GSK Investigational Site Not yet recruiting Pittsburgh, Pennsylvania, United States, 15232 Contact: US GSK Clinical Trials Call Center    877-379-3718    GSKClinicalSupportHD@gsk.com    Contact: EU GSK Clinical Trials Call Centre    877-379-3718    GSKClinicalSupportHD@gsk.com    United States, Texas GSK Investigational Site Recruiting San Antonio, Texas, United States, 78240 Contact: US GSK Clinical Trials Call Center    877-379-3718    GSKClinicalSupportHD@gsk.com    Contact: EU GSK Clinical Trials Call Centre    877-379-3718    GSKClinicalSupportHD@gsk.com    Principal Investigator: Anthony Tolcher          Australia, New South Wales GSK Investigational Site Not yet recruiting Darlinghurst, New South Wales, Australia, 2010 Contact: US GSK Clinical Trials Call Center    877-379-3718    GSKClinicalSupportHD@gsk.com    Contact: EU GSK Clinical Trials Call Centre    877-379-3718    GSKClinicalSupportHD@gsk.com    Australia, Victoria GSK Investigational Site Not yet recruiting Melbourne, Victoria, Australia, 3000 Contact: US GSK Clinical Trials Call Center    877-379-3718    GSKClinicalSupportHD@gsk.com    Contact: EU GSK Clinical Trials Call Centre    877-379-3718    GSKClinicalSupportHD@gsk.com    Canada, Ontario GSK Investigational Site Not yet recruiting Ottawa, Ontario, Canada, K1H 8L Contact: US GSK Clinical Trials Call Center    877-379-3718    GSKClinicalSupportHD@gsk.com    Contact: EU GSK Clinical Trials Call Centre    877-379-3718    GSKClinicalSupportHD@gsk.com    GSK Investigational Site Not yet recruiting Toronto, Ontario, Canada, M5G 2M Contact: US GSK Clinical Trials Call Center    877-379-3718    GSKClinicalSupportHD@gsk.com    Contact: EU GSK Clinical Trials Call Centre    877-379-3718    GSKClinicalSupportHD@gsk.com 收起 <<
NCT00945282 Infection, Human Immunodeficie... 展开 >>ncy Virus 收起 << Phase 2 Completed - Argentina ... 展开 >> GSK Investigational Site Buenos Aires, Argentina, B1602DBG 收起 <<
NCT02705807 Cardiovascular Disease Phase 4 Completed - Japan ... 展开 >> GSK Investigational Site Okayama, Japan, 701-1192 收起 <<
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

1.25mL

0.25mL

0.13mL

6.26mL

1.25mL

0.63mL

12.52mL

2.50mL

1.25mL
参考文献

[1]Schneider R, Reiners C. The effect of levothyroxine therapy on bone mineral density: a systematic review of the literature. Exp Clin Endocrinol Diabetes. 2003 Dec;111(8):455-70.

[2]Nilsson SF, Peterson PA. Studies on thyroid hormone-binding proteins. I. The subunit structure of human thyroxine-binding globulin and its interaction with ligands. J Biol Chem. 1975 Nov 10;250(21):8543-53.

[3]Arici M, Oztas E, Yanar F, Aksakal N, Ozcinar B, Ozhan G. Association between genetic polymorphism and levothyroxine bioavailability in hypothyroid patients. Endocr J. 2018 Mar 28;65(3):317-323

[4]Benvenga S. L-T4 Therapy in the Presence of Pharmacological Interferents. Front Endocrinol (Lausanne). 2020 Dec 22;11:607446

[5]Fadeyev VV, Morgunova TB, Melnichenko GA, Dedov II. Combined therapy with L-thyroxine and L-triiodothyronine compared to L-thyroxine alone in the treatment of primary hypothyroidism. Hormones (Athens). 2010 Jul-Sep;9(3):245-52

[6]Stasiolek M, Dedecjus M, Adamczewski Z, Sliwka PW, Brzezinski J, Lewinski A. Effect of L-thyroxine treatment on peripheral blood dendritic cell subpopulations in patients with Hashimoto's thyroiditis. Folia Histochem Cytobiol. 2014;52(2):138-43

[7]Kweon KH, Park BH, Cho CG. The effects of L-thyroxine treatment on QT dispersion in primary hypothyroidism. J Korean Med Sci. 2007 Feb;22(1):114-6